Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05404542 · ClinicalTrials.gov registry record · Phase 1
To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05404542 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT05404542, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The primary purpose is to assess the effect of renal impairment on the PK of tavapadon following administration of a single oral dose in participants with severe renal impairment relative to age, body weight, and sex-matched participants with normal renal function.
Interventions
- DRUG Tavapadon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-05-10 |
| Est. Completion | 2023-08-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05404542
The ClinicalTrials.gov registry entry for NCT05404542 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tavapadon is the first listed.
NCT05404542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05404542 about?
NCT05404542 is a clinical study titled "To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function". The primary purpose is to assess the effect of renal impairment on the PK of tavapadon following administration of a single oral dose in participants with severe renal impairment relative to age, body weight, and sex-matched participants with normal renal function.
What is the current status of trial NCT05404542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-05-10. Estimated completion is 2023-08-14.
What interventions are being tested in trial NCT05404542?
The interventions under investigation include: Tavapadon (DRUG).
Who is sponsoring clinical trial NCT05404542?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.